All News Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe Other stock markets 04:14:50 2024-04-18 am EDT			5-day change	1st Jan Change
84.64 ^CHF	-0.25%		-0.98%	-0.09%

Apr. 17	Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years	MT
Apr. 17	Novartis: positive efficacy data in MS	CF

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years	Apr. 17	MT
Novartis: positive efficacy data in MS	Apr. 17	CF
Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	DJ
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	GL
Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB?s Bimzelx Poised to Further Disrupt the Market	Apr. 16	CI
Novartis reports positive interim results for Fabhalta	Apr. 16	CF
Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial	Apr. 15	MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 15	DJ
Novartis' Fabhalta Found to Lower Disease Marker in Kidney Disease Patients	Apr. 15	MT
Novartis Gets Priority Review for Kidney Disease Treatment	Apr. 15	DJ
New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	Apr. 15	DJ
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	Apr. 15	GL
Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta	Apr. 15	CI
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	Apr. 12	AQ
MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis	Apr. 12	AQ
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	Apr. 12	MT
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares	Apr. 11	DJ
Novartis: licensing agreement in prostate cancer	Apr. 11	CF
Novartis: MorphoSys Board recommends tender offer	Apr. 11	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

NOVARTIS : Novartis on course to set new highs

February 20, 2024 at 11:30 am EST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT